Coeptis Therapeutics Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ZSQR$2.79-17.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |
| SALES | ||||
| Sales | $– | $– | $– | $– |
| Total sales | – | – | – | – |
| Cost of goods | – | – | – | – |
| Gross profit | – | – | – | – |
| OPERATING EXPENSES | ||||
| Research and development expense | 811,784 | 5,072,938 | 1,987,670 | 5,654,897 |
| Salary expense | 378,740 | 379,357 | 1,283,198 | 1,019,201 |
| Amortization expense | 250,000 | 250,000 | 750,000 | 750,000 |
| Professional services expense | 431,304 | 1,801,081 | 2,476,392 | 9,651,391 |
| Stock based compensation expense | 96,888 | 113,301 | 805,347 | 348,993 |
| General and administrative expenses | 173,073 | 272,131 | 584,667 | 687,963 |
| Selling and marketing expense | – | 12,412 | 5,000 | 12,711 |
| Total operating expenses | 2,141,789 | 7,901,220 | 7,892,274 | 18,125,156 |
| LOSS FROM OPERATIONS | (2,141,789) | (7,901,220) | (7,892,274) | (18,125,156) |
| OTHER INCOME (EXPENSE) | ||||
| Interest expense | (50,926) | (19,800) | (317,487) | (93,853) |
| Royalties and licensing fees | – | (15,000) | – | (15,000) |
| Other income (expense) | 51,558 | (23,601) | 146,246 | (23,566) |
| Loss on write down of assets | (37,257) | – | (37,257) | – |
| Gain on change in fair value of derivative liability warrants | 349,500 | 1,609,125 | 235,125 | 746,625 |
| TOTAL OTHER INCOME, NET | 312,875 | 1,550,724 | 26,627 | 614,206 |
| LOSS BEFORE INCOME TAXES | (1,828,914) | (6,350,494) | (7,865,647) | (17,510,948) |
| PROVISION FOR INCOME TAXES (BENEFIT) | – | – | – | – |
| NET LOSS | (1,828,914) | (6,350,494) | (7,865,647) | (17,510,948) |
| Net loss attributable to noncontrolling interests | – | – | – | – |
| NET LOSS ATTRIBUTABLE TO COEPTIS THERAPEUTICS HOLDINGS, INC. | $(1,828,914) | $(6,350,494) | $(7,865,647) | $(17,510,948) |
| LOSS PER SHARE | ||||
| Loss per share, basic and fully diluted | $(0.05) | $(0.24) | $(0.21) | $(0.76) |
| Weighted average number of common shares outstanding | 39,806,505 | 26,650,210 | 37,640,436 | 22,957,402 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.